The Thrombophilia Gene Panel by NGS evaluates genetic variants that increase the risk of abnormal blood clot formation. Metropolis Healthcare performs advanced sequencing using an EDTA blood sample to detect key mutations linked to inherited thrombophilia. This test supports early diagnosis in individuals with unexplained clots or a strong family history. It also helps guide preventive care and long-term management strategies.
Price:
Rs. 23,625.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes:G0332
Frequently Asked Questions (FAQ's):
What does the Thrombophilia Gene Panel test detect?
It identifies genetic mutations associated with increased clotting risk, such as Factor V Leiden, Prothrombin gene variants, and other thrombophilia-related genes.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-precision Next-Generation Sequencing (NGS) to analyze multiple genes from a simple EDTA blood sample.
Who should consider taking this test?
Individuals with recurrent deep vein thrombosis, pulmonary embolism, pregnancy loss, or a family history of thrombosis should consider this panel.
Why is this test important?
It helps determine whether a genetic predisposition is contributing to clot formation, enabling timely intervention and preventive care.
Can the results help guide treatment?
Yes, identifying specific mutations can help doctors personalize anticoagulation therapy and long-term monitoring.
How reliable are the results?
Metropolis Healthcare follows strict quality protocols and advanced sequencing workflows to deliver accurate and clinically validated results.
Is this test useful before pregnancy or fertility treatment?
Yes, it helps assess clotting risk and supports safer pregnancy planning and management.
Does this test provide information for family members?
Yes, results may guide screening and risk assessment for relatives who may also carry thrombophilia-related mutations